OBJECTIVE： To evaluate the therapeutic efficacy and safety of olodaterol for chronic obstructive pulmonary disease（COPD）， and to provide evidence-based reference in clinic. METHODS： Retrieved from PubMed， Cochrane Library， CNKI， Wanfang database， CBM and VIP， RCTs about olodaterol use alone or combination （trial group） versus tiotropium bromide or placebo （control group） in the treatment of COPD were collected. Meta-analysis was conducted by using Rev Man 5.3 statistical software after data extraction and quality evaluation with bias risk evaluation tool of Cochrane system evaluator manual 5.1.0. RESULTS： A total of 17 RCTs were included， involving 9 627 patients. Results of Meta-analysis demonstrated that FEV1 [MD＝0.08，95％CI（0.03，0.13），P＝0.001]，FVC [MD＝0.12，95％CI（0.03，0.22），P＝0.01] and FEV1％pred [MD＝0.77，95％CI（0.15，1.39），P＝0.02] of trial group were significantly better than those of control group after treatment， with statistical significance. In terms of safety， the incidence of total ADR [OR＝1.02，95％CI（0.93，1.12），P＝0.69]， serious ADR [OR＝1.04，95％CI（0.91，1.20），P＝0.56]， COPD exacerbation [OR＝0.88，95％CI（0.77，1.01），P＝0.07]， cough [OR＝1.07，95％CI（0.80，1.44），P＝0.64]， headache [OR＝0.75，95％CI（0.53，1.05），P＝0.10]， dyspnea [OR＝0.83，95％CI（0.61，1.15），P＝0.27]， nasopharyngitis [OR＝1.11，95％CI（0.91，1.36），P＝0.31] and upper respiratory tract infection [OR＝1.13，95％CI（0.87，1.46），P＝0.36] in trial group were similar to control group， without statistical significance. CONCLUSIONS： Olodaterol can significantly improve lung function in patients with COPD and delay disease progression without increasing ADR in patients.